GlassScriptPhysician profile
Rafael R Lopez
NPI 1124006358
$2,882.34
in general payments reported to CMS, 2019-2025
26 companies · $537 in 2025
The $537 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $702 · 2020: $55.51 · 2021: $341 · 2022: $388 · 2023: $278 · 2024: $583 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,163 · Education: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,162.85 |
| Education | $234.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $752.62 | 2019-2025 | Xtandi |
| Antares Pharma, INC. | $542.36 | 2019-2025 | Xyosted |
| Janssen Biotech, INC. | $324.34 | 2023-2025 | Erleada |
| Pfizer INC. | $238.61 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $111.73 | 2019-2024 | Adstiladrin |
| Abbvie INC. | $98.50 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $80.36 | 2023-2024 | Gemtesa, Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $79.51 | 2019-2025 | |
| Coloplast Corp | $70.68 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $60.94 | 2019 | |
| Myovant Sciences INC. | $55.14 | 2021 | |
| Endo Pharmaceuticals INC. | $53.41 | 2019-2022 | |
| Boston Scientific Corporation | $50.83 | 2019-2023 | |
| Verity Pharmaceuticals INC. | $49.08 | 2024 | Trelstar |
| Dentsply Ih INC. | $47.42 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $41.30 | 2024-2025 | Eligard, Jatenzo |
| Novartis Pharmaceuticals Corporation | $36.44 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Conmed Corporation | $29.98 | 2024 | Airseal |
| Axonics, INC. | $20.23 | 2024 | Axonics |
| Telix Pharmaceuticals | $19.46 | 2023 | Illuccix |
| Convatec INC. | $19.20 | 2023 | |
| Halozyme INC | $18.63 | 2023 | |
| Mission Pharmacal Company | $15.92 | 2019 | |
| Photocure INC | $15.85 | 2024 | Cysview |
| Blue Earth Diagnostics | $14.74 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.